Perrigo confirms patent challenge for generic version of Jublia

Perrigo Company announced that Valeant Pharmaceuticals North America, Valeant Pharmaceuticals Ireland, Dow Pharmaceuticals Sciences and Kaken Pharmaceuticals initiated patent litigation on September 21, 2018 in the United States District Court for the District of New Jersey regarding Perrigo’s Paragraph IV Abbreviated New Drug Application for efinaconazole topical solution 10%, asserting patents listed in the Orange Book for Jublia. This action formally initiates the litigation process under the Hatch-Waxman Act. Jublia Topical Solution 10%, is indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. Annual market sales for the 12 months ending July 2018 were $276M as measured by IQVIA.
https://thefly.com/landingPageNews.php?id=2797857